Lipooligosaccharide locus class of Campylobacter jejuni: Sialylation is not needed for invasive infection

Clinical Microbiology and Infection

Volumn 20, Issue 6, 2014, Pages 524-529

  Ellstrom P ^a   Feodoroff, B ^b   Hanninen M L ^c   Rautelin, H ^a,b,d  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Bacteraemia; Blood; Campylobacter; Infection; Invasive; Lipooligosaccharide; MLST; Serum resistance

Indexed keywords

LIPOOLIGOSACCHARIDE; VIRULENCE FACTOR; GAMMA GLUTAMYLTRANSFERASE; LIPID-LINKED OLIGOSACCHARIDES; LIPOPOLYSACCHARIDE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIAL GENE; BACTERIAL SURVIVAL; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; CAMPYLOBACTER ENTERITIS; CAMPYLOBACTER JEJUNI; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; SIALYLATION; CAMPYLOBACTERIOSIS; CLASSIFICATION; COHORT ANALYSIS; FEMALE; FINLAND; GENETICS; MALE; METABOLISM; MICROBIOLOGY; MIDDLE AGED; MULTILOCUS SEQUENCE TYPING; PATHOGENICITY; POLYMERASE CHAIN REACTION; SECRETION (PROCESS); SERUM BACTERICIDAL ACTIVITY;

BACTERIA (MICROORGANISMS); CAMPYLOBACTER; CAMPYLOBACTER JEJUNI;

BACTEREMIA; BLOOD BACTERICIDAL ACTIVITY; CAMPYLOBACTER INFECTIONS; CAMPYLOBACTER JEJUNI; COHORT STUDIES; FEMALE; FINLAND; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; MULTILOCUS SEQUENCE TYPING; POLYMERASE CHAIN REACTION; VIRULENCE FACTORS;

EID: 84904436972     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12382     Document Type: Article

References (31)

1. Blaser MJ. Epidemiologic and clinical features of Campylobacter jejuni infections. J Infect Dis 1997; 176(suppl 2): S103-S105.
2. EFSA (European Food Safety Authority), ECDC (European Centre for Disease Prevention and Control). The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2011. EFSA J 2013; 11: 3129-3378.
3. Blaser M, Engberg J. Clinical aspects of Campylobacter jejuni and Campylobacter coli infections. Nachamkin I, Szymanski CM, Blazer MJ, eds. Campylobacter, 3rd edn. Washington, DC: ASM Press, 2008; 99-121.
4. Koga M, Gilbert M, Takahashi M et al. Comprehensive analysis of bacterial risk factors for the development of Guillain-Barré syndrome after Campylobacter jejuni enteritis. J Infect Dis 2006; 193: 547-555.
5. Guerry P, Ewing CP, Hickey TE, Prendergast MM, Moran AP. Sialylation of lipooligosaccharide cores affects immunogenicity and serum resistance of Campylobacter jejuni. Infect Immun 2000; 68: 6656-6662.
6. Habib I, Louwen R, Uyttendaele M et al. Correlation between genotypic diversity, lipooligosaccharide gene locus class variation, and caco-2 cell invasion potential of Campylobacter jejuni isolates from chicken meat and humans: contribution to virulotyping. Appl Environ Microbiol 2009; 75: 4277-4288.
7. Louwen R, Heikema A, van Belkum A et al. The sialylated lipooligosaccharide outer core in Campylobacter jejuni is an important determinant for epithelial cell invasion. Infect Immun 2008; 76: 4431-4438.
8. Louwen R, Nieuwenhuis EE, van Marrewijk L et al. Campylobacter jejuni translocation across intestinal epithelial cells is facilitated by ganglioside-like lipooligosaccharide structures. Infect Immun 2012; 80: 3307-3318.
9. Bacon DJ, Alm RA, Burr DH et al. Involvement of a plasmid in virulence of Campylobacter jejuni 81-176. Infect Immun 2000; 68: 4384-4390.
10. Fearnley C, Manning G, Bagnall M, Javed MA, Wassenaar TM, Newell DG. Identification of hyperinvasive Campylobacter jejuni strains isolated from poultry and human clinical sources. J Med Microbiol 2008; 57: 570-580.
11. Konkel ME, Kim BJ, Rivera-Amill V, Garvis SG. Identification of proteins required for the internalization of Campylobacter jejuni into cultured mammalian cells. Adv Exp Med Biol 1999; 473: 215-224.
12. Feodoroff B, Ellström P, Hyytiainen H, Sarna S, Hänninen ML, Rautelin H. Campylobacter jejuni isolates in Finnish patients differ according to the origin of infection. Gut Pathog 2010; 2: 22-28.
13. Park SF, Richardson PT. Molecular characterization of a Campylobacter jejuni lipoprotein with homology to periplasmic siderophore-binding proteins. J Bacteriol 1995; 177: 2259-2264.
14. Muraoka WT, Zhang Q. Phenotypic and genotypic evidence for l-fucose utilization by Campylobacter jejuni. J Bacteriol 2011; 193: 1065-1075.
15. Stahl M, Friis LM, Nothaft H et al. L-fucose utilization provides Campylobacter jejuni with a competitive advantage. Proc Natl Acad Sci USA 2011; 108: 7194-7199.
16. Feodoroff B, Lauhio A, Ellström P, Rautelin H. A nationwide study of Campylobacter jejuni and Campylobacter coli bacteremia in Finland over a 10-year period, 1998-2007, with special reference to clinical characteristics and antimicrobial susceptibility. Clin Infect Dis 2011; 53: e99-e106.
17. Feodoroff B, de Haan CPA, Ellström P, Sarna S, Hänninen ML, Rautelin H. Clonal distribution and virulence properties of Campylobacter jejuni blood isolates: implications of ST-677 clonal complex as an invasive pathogen. Emerg Infect Dis 2013; 19: 1653-1655.
18. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
19. Blaser MJ, Smith PF, Kohler PF. Susceptibility of Campylobacter isolates to the bactericidal activity of human serum. J Infect Dis 1985; 151: 227-235.
20. Parker CT, Gilbert M, Yuki N, Endtz HP, Mandrell RE. Characterization of lipooligosaccharide-biosynthetic loci of Campylobacter jejuni reveals new lipooligosaccharide classes: evidence of mosaic organizations. J Bacteriol 2008; 190: 5681-5689.
21. Parker CT, Horn ST, Gilbert M, Miller WG, Woodward DL, Mandrell RE. Comparison of Campylobacter jejuni lipooligosaccharide biosynthesis loci from a variety of sources. J Clin Microbiol 2005; 43: 2771-2781.
22. Mortensen NP, Kuijf ML, Ang CW et al. Sialylation of Campylobacter jejuni lipo-oligosaccharides is associated with severe gastro-enteritis and reactive arthritis. Microbes Infect 2009; 11: 988-994.
23. Gilbert M, Karwaski MF, Bernatchez S et al. The genetic bases for the variation in the lipo-oligosaccharide of the mucosal pathogen, Campylobacter jejuni. Biosynthesis of sialylated ganglioside mimics in the core oligosaccharide. J Biol Chem 2002; 277: 327-337.
24. Ellström P, Feodoroff B, Hänninen ML, Rautelin H. Characterization of clinical Campylobacter jejuni isolates with special emphasis on lipooligosaccharide locus class, putative virulence factors and host response. Int J Med Microbiol 2013; 303: 134-139.
25. Islam Z, van Belkum A, Wagenaar JA et al. Comparative genotyping of Campylobacter jejuni strains from patients with Guillain-Barré syndrome in Bangladesh. PLoS ONE 2009; 4: e7257.
26. Revez J, Hänninen ML. Lipooligosaccharide locus classes are associated with certain Campylobacter jejuni multilocus sequence types. Eur J Clin Microbiol Infect Dis 2012; 31: 2203-2209.
27. Blaser MJ, Newell DG, Thompson SA, Zechner EL. Pathogenesis of Campylobacter fetus. Nachamkin I, Szymanski CM, Blaser MJ, eds. Campylobacter, 3rd edn. Washington, DC: ASM Press, 2008; 401-428.
28. Blaser MJ, Perez GP, Smith PF et al. Extraintestinal Campylobacter jejuni and Campylobacter coli infections: host factors and strain characteristics. J Infect Dis 1986; 153: 552-559.
29. Keo T, Collins J, Kunwar P, Blaser MJ, Iovine NM. Campylobacter capsule and lipooligosaccharide confer resistance to serum and cationic antimicrobials. Virulence 2011; 2: 30-40.
30. de Haan CP, Llarena AK, Revez J, Hänninen ML. Association of Campylobacter jejuni metabolic traits with multilocus sequence types. Appl Environ Microbiol 2012; 78: 5550-5554.
31. Zautner AE, Herrmann S, Corso J, Tareen AM, Alter T, Gross U. Epidemiological association of different Campylobacter jejuni groups with metabolism-associated genetic markers. Appl Environ Microbiol 2011; 77: 2359-2365.